Forsta AP Fonden Has $4.66 Million Holdings in The Clorox Company (NYSE:CLX)

Forsta AP Fonden trimmed its position in shares of The Clorox Company (NYSE:CLX) by 5.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,700 shares of the company’s stock after selling 1,800 shares during the quarter. Forsta AP Fonden’s holdings in Clorox were worth $4,661,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Catalyst Capital Advisors LLC acquired a new stake in Clorox during the 3rd quarter valued at $54,000. Los Angeles Capital Management LLC grew its holdings in shares of Clorox by 5.6% during the third quarter. Los Angeles Capital Management LLC now owns 191,919 shares of the company’s stock worth $31,266,000 after purchasing an additional 10,149 shares during the last quarter. Advisors Asset Management Inc. increased its stake in shares of Clorox by 43.4% in the third quarter. Advisors Asset Management Inc. now owns 29,865 shares of the company’s stock valued at $4,865,000 after buying an additional 9,037 shares in the last quarter. Natixis Advisors LLC raised its holdings in shares of Clorox by 8.3% in the third quarter. Natixis Advisors LLC now owns 63,476 shares of the company’s stock valued at $10,341,000 after buying an additional 4,839 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Clorox by 1.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 723,906 shares of the company’s stock worth $117,932,000 after buying an additional 13,038 shares in the last quarter. Institutional investors own 78.53% of the company’s stock.

Clorox Stock Down 1.2 %

Shares of NYSE:CLX opened at $158.60 on Friday. The company has a 50 day moving average price of $162.98 and a two-hundred day moving average price of $158.03. The company has a debt-to-equity ratio of 11.08, a quick ratio of 0.62 and a current ratio of 1.00. The company has a market capitalization of $19.63 billion, a PE ratio of 55.26, a PEG ratio of 2.91 and a beta of 0.42. The Clorox Company has a 52 week low of $127.60 and a 52 week high of $171.37.

Clorox (NYSE:CLX) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.50. Clorox had a net margin of 4.78% and a return on equity of 316.08%. The business had revenue of $1.76 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same quarter in the prior year, the company earned $0.49 EPS. The firm’s quarterly revenue was up 27.0% on a year-over-year basis. Analysts forecast that The Clorox Company will post 6.86 earnings per share for the current year.

Clorox Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 29th will be given a dividend of $1.22 per share. This represents a $4.88 dividend on an annualized basis and a dividend yield of 3.08%. The ex-dividend date of this dividend is Wednesday, January 29th. Clorox’s dividend payout ratio is currently 170.04%.

Analyst Upgrades and Downgrades

CLX has been the subject of several research reports. Wells Fargo & Company upgraded shares of Clorox from an “underweight” rating to an “equal weight” rating and raised their price objective for the company from $155.00 to $157.00 in a research report on Tuesday, January 7th. JPMorgan Chase & Co. boosted their price objective on shares of Clorox from $167.00 to $171.00 and gave the stock a “neutral” rating in a research report on Thursday, January 16th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $150.00 price objective on shares of Clorox in a report on Thursday. TD Cowen raised Clorox from a “sell” rating to a “hold” rating and lifted their target price for the company from $155.00 to $170.00 in a research note on Wednesday, November 6th. Finally, Barclays cut their price target on Clorox from $139.00 to $130.00 and set an “underweight” rating on the stock in a research note on Friday, January 17th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, Clorox currently has an average rating of “Hold” and an average target price of $156.07.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.